Johnson & Johnson posted a loss in the first three months of the year as it booked a massive $6.9 billion charge related to its recently-agreed proposal to settle clai
Teva and partner Alvotech’s hopes of launching their biosimilar of AbbVie’s high-potency formulation of big-selling immunology drug Humira have been dashed, after the FDA
The influential Institute for Clinical and Economic Review (ICER) in the US has issued draft guidance suggesting that new gene therapies for sickle cell disease (SCD) from
Disgraced former biotech chief Elizabeth Holmes will start an 11-year prison sentence at the end of this month, after a federal judge denied her request to remain free whi
The FDA has convened a meeting of an advisory committee in June to consider the bid by Eisai and Biogen to convert their accelerated approval of Alzheimer’s disease therap
AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut